Evidence map›Paper›PMID 40539388›Full record

Observational studyAnnals of neurology2025

Deep Brain Stimulation for VPS16-Related Dystonia: A Multicenter Study.

Tatiana Svorenova, Luigi M Romito, Ahmet Kaymak, Eoin Mulroy, Laura Cif, Elena Moro, Kirsten E Zeuner, Simone Zittel, Jan Niklas Petry-Schmelzer, Doreen Gruber and 37 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Expanding the Genetic and Phenotypic Spectrum of DYT-VPS16: The Importance of Splice-Site Variants.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Tatiana Svorenova *Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.ORCID 0009-0006-5237-8736
Luigi M Romito *Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID 0000-0002-6772-1035
Ahmet Kaymak *The BioRobotics Institute, Scuola Superiore Sant' Anna, Pisa, Italy.
Eoin MulroyUnit of Functional Neurosurgery, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0002-0823-8916
Laura CifDepartment of Neurosurgery, Gui de Chauliac Hospital, University Hospital Montpellier, Montpellier, France.
Elena MoroGrenoble Alpes University, Division of Neurology, CHU of Grenoble, Grenoble Institute of Neurosciences, Grenoble, France.ORCID 0000-0002-7968-5908
Kirsten E ZeunerDepartment of Neurology, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Simone ZittelDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan Niklas Petry-SchmelzerDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0003-0749-3840
Doreen GruberMovement Disorders Hospital, Beelitz-Heilstätten, Germany.
Liesanne CentenDepartment of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Alberto AlbaneseDepartment of Neurology, IRCCS Fondazione Mondino, Pavia, Italy.
Miriama OstrozovicovaDepartment of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Vladimir HanDepartment of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Veronika MagocovaDepartment of Neurosurgery, P.J. Safarik University, Kosice, Slovak Republic.
Kamil KnorovskyDepartment of Neurosurgery, P.J. Safarik University, Kosice, Slovak Republic.
Aurelia KollovaDepartment of Neurosurgery, P.J. Safarik University, Kosice, Slovak Republic.
Barbara GaravagliaUnit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Nico Golfrè-AndreasiParkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Chiara RealeUnit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Alberto MazzoniThe BioRobotics Institute, Scuola Superiore Sant' Anna, Pisa, Italy.
Giovanna ZorziDepartment of Child Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Roberto EleopraParkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Vincenzo LeviNeurosurgery Department, Functional Neurosurgery Unit, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.
Thomas FoltynieUnit of Functional Neurosurgery, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-0752-1813
Patricia LimousinUnit of Functional Neurosurgery, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Harith AkramUnit of Functional Neurosurgery, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Ludvic ZrinzoUnit of Functional Neurosurgery, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Francesca MagrinelliDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-4706-6245
David MurphyDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Henry HouldenDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.
Manju A KurianDevelopmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Institute of Child Health, London, UK.
Claudio BaiataDivision of Neurology, CHU of Grenoble, Grenoble, France.
Steffen PaschenDepartment of Neurology, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
Katja LohmannInstitute of Neurogenetics, University of Luebeck, Luebeck, Germany.ORCID 0000-0002-5121-1460
Jens VolkmannDepartment of Neurology, University of Würzburg, Würzburg, Germany.
Wolfgang HamelDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael T BarbeDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Martje E van EgmondDepartment of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Maj TijssenDepartment of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Lubos AmbroCenter for Interdisciplinary Biosciences, Technology and Innovation Park, P.J. Safarik University, Kosice, Slovak Republic.
Veronika JurkovaDepartment of Health Psychology and Research Methodology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovak Republic.
Robert JechDepartment of Neurology, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Praha, Prague, Czech Republic.
Petra HavrankovaDepartment of Neurology, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Praha, Prague, Czech Republic.
Juliane WinkelmannInstitute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Michael ZechInstitute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Matej Skorvanek *Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-22-0279American Parkinson Disease Association 1282403Bundesministerium für Bildung und ForschungCzech Ministry of Health AZV NW24-04-00067David Pearlman Charitable FoundationDeutsche Forschungsgemeinschaft DFG 458949627Deutsche Forschungsgemeinschaft LO1555/10-1Deutsche Forschungsgemeinschaft WI 1820/14-1Deutsche Forschungsgemeinschaft ZE 1213/2-1Edmond J. Safra Fellowship in Movement DisordersEdmond J. Safra Movement Disorders Research Career Development Award MJFF-023893Else Kröner-Fresenius-Stiftung 2022_EKSE.185EU Recovery and Resilience Plan "Large projects for excellent researchers" 09I03-03-V03-00007European Joint Programme on Rare Diseases, EJP RD Joint Transnational Call 2022Excellence Strategy of the Federal Government and the LänderFondazione Pierfranco e Luisa MarianiInstitute for Advanced Study, Technische Universität MünchenMinistero della SaluteNextGenerationEU, Programme EXCELES, ID Project No. L X22NPO5107Parkinson's UK G-2401PreDYT (PREdictive biomarkers in DYsTonia) 01GM2302University College London Hospitals Biomedical Research Centre BRC1287/TN/FM/101410
6 · The paper itself

Abstract

objectiveThe objective was to evaluate the effects of deep brain stimulation (DBS) in an international cohort of patients with VPS16-related dystonia.

methodsThis observational study collected preoperative and postoperative demographic, clinical, stimulation, genetic, neuroimaging, and neurophysiological data of medically refractory DYT-VPS16 patients with implanted DBS in 10 international centers. Motor symptoms and disability outcomes were assessed using the Burke-Fahn-Marsden Dystonia Rating Scale Motor (BFMDRS-M) and Disability (BFMDRS-D) scales. A cut-off threshold for considering response to DBS was set at 25% of BFMDRS-M improvement at the last follow-up (FU) compared to baseline.

resultsThe cohort consisted of 26 participants (17 men, 65.4%). Age at dystonia onset and surgery was 17.8 ± 10.9 and 35.3 ± 14.8 years, respectively. At the last FU, 102.5 ± 57.3 months (range, 2-216), the mean BFMDRS-M improvement was 41.6 ± 37.3% (26/26 patients) and 34.8 ± 42.6% for the BFMDRS-D (23/26 patients). Most patients (19/26, 73%) were considered responders. Higher motor improvement was associated with stimulation of the ventroposterior portion of the internal globus pallidus. A significant inverse relationship was observed between improvement in BFMDRS-M at last FU, and the presence of spasticity (p = 0.027) and fixed skeletal deformities (p = 0.001) before surgery. Non-responders had a younger age at disease onset and at implantation, shorter disease duration at DBS surgery, and higher baseline BFMDRS scores.

interpretationDBS was an effective treatment for three-quarters of patients with pathogenic VPS16 variants in our cohort. Mean motor improvement was most pronounced at the 1-year FU, but persisted at the last FU despite disease progression. ANN NEUROL 2025;98:711-725.

Indexed as

Deep Brain StimulationDystoniaDystonic DisordersAdolescentAdultChildCohort StudiesFemaleHumansMaleMiddle AgedTreatment OutcomeYoung Adult

Identifiers

PMID40539388
PMCPMC12542321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.